About Us
Altor BioScience Corporation is a biopharmaceutical company developing a new class of therapeutic products for the treatment of cancer, viral infections, and autoimmune diseases.
Technology Platforms
STAR™ Technology Platform - The Company’s proprietary Soluble T-cell Antigen Receptor (STAR™) technology enables the recognition of novel targets on cancerous or virally infected cells which cannot be seen by traditional monoclonal antibodies.
Tissue Factor Antagonists Platform - Monoclonal antibody based antagonists are being explored in clinical development to treat a variety of life-threatening inflammatory diseases and cancer.
IL-15 Platform - IL-15 agonists, antagonists and protein scaffolds are being utilized to create novel immune molecules for treatment of cancer, infections and inflammation.
Product Development
First-in-class product candidates derived from the STAR™ and Tissue Factor Antagonists Platforms are currently in mid-stage clinical trials. The lead product from the IL-15 Platform will be in clinical development in early 2013. This strong product pipeline is further reinforced by the numerous other product candidates that have completed proof-of-principle studies in animal models and are at the preclinical development stage.
STAR™ Multimer Reagents
Altor has launched an exciting new class of innovative research products based on its proprietary STAR™ technology. These products enable the detection of novel disease targets presented on the surface of cells and tissues which are not detectable by antibodies. Altor continues to expand the reagent product portfolio.